- The iShares Nasdaq Biotechnology ETF includes both COVID-19 and other plays.
- The ETF is up by 26% during the last year and there are questions around further growth.
- While some analysts have a neutral stance, there are some indications which point to more upside, despite uncertainties, in 2021.
- With biotechs already having proven their worth to rapidly come up with a COVID cure, it is unlikely that the U.S. authorities will implement policies which adversely impact these innovators that are of such a great help to mankind.
For further details see:
iShares Nasdaq Biotechnology ETF: Continuous Innovation For Mankind